Investor News / RNS

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published...

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly's cancer drug discovery research....

ValiRx, the cancer therapeutics company, has signed a new agreement with Physiomics to use its in silico simulations of cellular processes to reduce the development time and costs associated in identifying new therapeutic compounds for the treatment of cancers. ...

Physiomics plc is pleased to announce that it has been selected to participate in the TEMPO (Temporal Genomics for Tailored Chemotherapeutics) Project as one of four Industry partners working closely with four distinguished European academic research groups...

Physiomics plc has developed a sophisticated addition to its core cell growth model showing why different cancer cells respond in different ways to an innovative new class of anti-cancer drugs. This was presented at the International Conference on Systems Biology meeting in Boston, USA, 19th-21st October 2005....

Physiomics and Bayer Technology Services GmbH (BTS) have signed an agreement under which BTS has appointed Physiomics as a distributor of its PK-Sim® pharmacokinetic modelling products and services for a renewable five-year period....

Physiomics plc has received formal notification from the UK Patent Office of registration to it in the UK of European Patent 0 937 286, which covers its SystemCell™ simulation technology. The corresponding US Patent 6,446,055 was granted on 3 September 2002 and assigned to Physiomics on 14 November 2002...

Physiomics plc and Cronos Therapeutics Ltd (now ValiRx plc) have entered into an alliance whereby Physiomics will use its novel in silico technology to select optimal targets for the highly-selective GeneICE technology from Cronos Therapeutics. The alliance will then codevelop the lead GeneICE constructs....

Bayer Technology Services, the engineering and applied science spin-off company of Bayer AG, and Physiomics plc announced today an agreement to cooperate in the field of clinical response prediction....